眼科

• 论著 • 上一篇    下一篇

玻璃体注射雷珠单抗治疗老年性黄斑变性黄斑水肿与视网膜静脉阻塞性黄斑水肿的短期疗效观察

刘益帆  刘冬瑞  徐进  刘平   

  1. 150001 哈尔滨医科大学第一附属医院眼科
  • 收稿日期:2016-11-19 出版日期:2017-03-25 发布日期:2017-03-29
  • 通讯作者: 刘平,Email: pingliu53@126.com
  • 基金资助:

    国家自然科学基金(81470618)

The short-term clinical effects of the ranibizumab intravitreal injection on age-related macular degeneration macular edema and retinal vein occlusion macular edema#br#  

LIU Yi-fan, LIU Dong-rui, XU Jin, LIU Ping   

  1. Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
  • Received:2016-11-19 Online:2017-03-25 Published:2017-03-29
  • Contact: LIU Ping, Email: pingliu53@126.com

摘要:

目的 观察玻璃体注射雷珠单抗治疗老年黄斑变性黄斑水肿(AMD-ME)与视网膜静脉阻塞性黄斑水肿(RVO-ME)的短期临床效果。设计 回顾性病例系列。研究对象 2015年10月至2016年7月确诊为AMD-ME 及RVO-ME 的患者共30例(30眼),各15例(15眼)。方法 患眼接受玻璃体注射雷珠单抗(0.5 mg/0.05 ml)治疗,采用1+PRN的注射方法,比较治疗前和治疗后 1 天、1个月最佳矫正视力(BCVA)、眼压(IOP)、黄斑中心凹视网膜厚度(CMT)、注射后消除的水肿高度,评价每次随访时检查结果。主要指标 BCVA、CMT、消除的水肿高度、IOP。结果 AMD-ME组及RVO-ME 组注射雷珠单抗后1天、1个月的BCVA均较术前提高(P=0.000、0.000)。AMD-ME组 及RVO-ME 组每次治疗前和治疗后1个月CMT厚度均降低(P=0.000、0.000)。治疗过程中患者眼压与治疗前比较并无明显变化 (P=0.096、0.066、0.213、0.088、0.240、0.337)。结论 玻璃体注射雷珠单抗治疗 AMD-ME 及 RVO-ME 在短期内均可减轻黄斑水肿和改善视力,两者治疗效果无明显差异。(眼科, 2017, 26: 120-124)

关键词: 雷珠单抗, 老年性黄斑变性, 视网膜静脉阻塞, 黄斑水肿

Abstract:

Objective To investigate the short-term clinical effects of the ranibizumab intravitreal injection on age related macular degeneration macular edema (AMD-ME) and retinal vein occlusion macular edema (RVO-ME). Design Retrospective case series. Participants 30 patients (30 eyes) with 15 AMD-ME and 15 RVO-ME. Methods All patients received ranibizumab 0.05 ml intravitreal injection, using 1+PRN injection algarism. The follow-up examinations were at 1 day, 1 month after the treatment. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were observed and compared between AMD-ME patients and RVO-ME patients before and after injection. Main Outcome Measures BCVA, CMT, IOP. Results The BCVA of both AMD-ME group and RVO-ME group improved significantly at 1 day and 1 month after the ranibizumab intravitreal injection (P=0.000, 0.000). The CMT reduced significantly for both group as well (P=0.000, 0.000). The IOP did not change significantly during the treatment (P=0.096, 0.066, 0.213, 0.088, 0.240, 0.337 for different time points). Conclusion Ranibizumab intravitreal injection can reduce macular edema and improve the visual activity in patients with AMD-ME or RVO-ME. The treatment effect was similar for AMD-ME and RVO-ME. (Ophthalmol CHN, 2017, 26: 120-124)
 

Key words: ranibizumab, age-related macular degeneration, retinal vein occlusion, macular edema